In a recent interview—produced by Onyx and published in Fortune—Dr. Shankar Musunuri shared more about the Company’s dedication to treating blindness diseases with a mission to make these therapies accessible globally. #CourageousInnovation onyxnewsroom.com/ocugen-has-a-c…
onyxnewsroom.com
Ocugen has a cure in sight
“The cost of gene therapies can reach millions of dollars per patient… Our goal is developing cost-effective treatments that can be accessible globally.”
$OCGN Foundation Fighting Blindess has several @Ocugen videos on their YouTube channel. youtu.be/N3oehg70fTs?si…
Today, Ocugen announced positive preliminary data from the Phase 1/2 OCU410 ArMaDa clinical trial. This data, along with data from the Phase 1/2 OCU410ST GARDian study and LCA data from the Phase 1/2 OCU400 study were presented at the clinical showcase bit.ly/490Nmc0 #GA
$OCGN love how the bears try to portray excited retail investors as pumpers and dumpers. Morons. We’re just regular people.
On Friday, November 8, 2024, Ocugen will host a conference call and live webcast to discuss the Company’s third quarter 2024 financial results and provide a business update. For more information on how to join, click here: bit.ly/3Uc6iyu
United States Trends
- 1. Mick Cronin N/A
- 2. Namjoon N/A
- 3. Deen N/A
- 4. #LCDLF6 N/A
- 5. Arizona State N/A
- 6. JT Toppin N/A
- 7. Tom Noonan N/A
- 8. Nebraska N/A
- 9. #YouTubeDOWN N/A
- 10. #River N/A
- 11. Iowa N/A
- 12. UCLA N/A
- 13. Pope N/A
- 14. Rupp N/A
- 15. Bobby Hurley N/A
- 16. Ramadan Mubarak N/A
- 17. Lent N/A
- 18. Stirtz N/A
- 19. June Carter N/A
- 20. Landon N/A
Something went wrong.
Something went wrong.